Loading organizations...
§ Private Profile · Waukesha, WI, USA
Prodesse is a technology company.
Prodesse Property Group offers comprehensive property management services for residential and commercial assets across the San Francisco Bay Area. The company delivers full-service operations, overseeing day-to-day management for property owners and ensuring quality living and working environments for tenants. Its approach integrates meticulous operational oversight with a strong emphasis on community and ethical practices within the real estate sector.
The company is a family-owned enterprise co-founded by Michael and Lynn Pierce. Michael Pierce brings over 37 years of experience in property management, having been active in apartment management, acquisition, and renovation since 1979, including prior roles at Essex Property Trust. Lynn Pierce, a Certified Public Accountant, leads the financial management and human resources functions, leveraging her extensive background in accounting and consulting since 1983. Their combined expertise forms the bedrock of Prodesse’s operational and ethical framework.
Prodesse serves building owners seeking diligent management of their investments and thousands of residents who occupy its managed properties. The company’s mission centers on providing excellent service while its vision, encapsulated as "Be Good. Do Good. Live Good," drives its commitment to ethical decision-making, community engagement, and a continuous effort to improve the spaces and lives it touches, aiming to leave a lasting positive impact.
Prodesse has raised $2.0M across 1 funding round.
Prodesse has raised $2.0M in total across 1 funding round.
Prodesse, Inc. was a biotechnology company specializing in molecular diagnostic reagents for infectious diseases, particularly respiratory pathogens. Founded in 1995 and based in Waukesha, Wisconsin, it developed real-time PCR assays like ProFlu+ for detecting influenza A/B and RSV, Pro hMPV+ for human metapneumovirus, and tests for Clostridium difficile.[1][2][3] These FDA-cleared products served clinical labs, offering rapid results (as little as 3 hours) compatible with platforms like Cepheid's SmartCycler, addressing the need for faster, more sensitive diagnostics over culture methods during outbreaks.[1][3] The company generated around $15 million in revenue before its acquisition by Gen-Probe in 2009 for $60 million (plus up to $25 million in milestones), accelerating its growth via Gen-Probe's global infrastructure.[2]
Prodesse was established in 1995 in Waukesha, Wisconsin, with about 20 employees focused on real-time multiplex PCR for critical infectious diseases.[3] Key leadership included Chief Science Officer Dr. Steven Visuri, who advanced dye technologies for multiplex assays compatible with multiple PCR platforms.[4] The idea emerged from the demand for rapid molecular diagnostics amid rising respiratory infections; pivotal was the 2008 FDA clearance of ProFlu+, the first real-time PCR test distinguishing influenza A/B and RSV, filling a gap in outbreak response.[1][2] Licensing deals with Biosearch Technologies (for quenchers/fluorophores) and Invitrogen bolstered its tech, enabling 4-plex assays.[4][5] Early traction built through U.S. FDA approvals and CE-marked products for Europe, culminating in Gen-Probe's acquisition in 2009.[1][2][6]
Prodesse rode the early 2000s wave of molecular diagnostics, shifting from slow culture-based tests to real-time PCR amid flu pandemics and antibiotic-resistant infections like C. difficile.[1][2] Timing was ideal post-2000s H1N1 threats, where speed mattered for infection control; market forces favored PCR's sensitivity in hospitals/labs.[1][3] It influenced the ecosystem by pioneering FDA-cleared multiplex respiratory panels, paving the way for integrated diagnostics acquired by Gen-Probe (now part of Hologic), which scaled these to global use and boosted EPS.[2][6]
Post-2009 acquisition, Prodesse integrated into Gen-Probe (rebranded under Hologic), evolving its assays into broader infectious disease portfolios amid rising demand for rapid testing—exemplified by COVID-19.[1][6] Next likely involves AI-enhanced multiplexing and point-of-care expansion, shaped by antimicrobial resistance trends and post-pandemic preparedness. Its legacy endures in modern diagnostics, influencing scalable molecular tools that Gen-Probe's infrastructure propelled from niche innovator to market accelerator.[2]
Prodesse has raised $2.0M across 1 funding round. Most recently, it raised $2.0M Seed in December 2001.
| Date | Round | Lead Investors | Other Investors | Status |
|---|---|---|---|---|
| Dec 1, 2001 | $2M Seed | — | — | Announced |
Prodesse has raised $2.0M in total across 1 funding round.